Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas
| Autor: | Jose M. Pimiento, Kevin G Neill, Jessica M. Frakes, Pamela J. Hodul, Evan S. Glazer, Gregory M. Springett, Mokenge P. Malafa, Sara E Hoffe, Domenico Coppola |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Pathology Malignancy 03 medical and health sciences 0302 clinical medicine medicine Carcinoma Acinar cell Humans Basal cell Carcinoma Acinar Cell business.industry General surgery Hematology General Medicine Middle Aged medicine.disease Pancreatic Neoplasms medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Acinar cell carcinoma of the pancreas Pancreas business |
| Zdroj: | ResearcherID |
| ISSN: | 1073-2748 |
| DOI: | 10.1177/107327481602300417 |
| Popis: | BackgroundAcinar cell carcinoma of the pancreas is a rare malignancy representing less than 1% of all pancreatic malignancies.MethodsWe report on a case series of 21 patients with acinar cell carcinoma of the pancreas treated at a high-volume quaternary center. A systematic review of the medical literature was performed that described typical therapeutic management approaches for acinar cell carcinoma of the pancreas and reported on disease control and survival rates. Data for the case series were obtained from a prospective database.ResultsIn our systematic review of 6 articles, study patients had a median age of 61 years, 66% were male, 52% had stage I/II disease, and 55% of lesions were located in the pancreatic head. The rates of median survival were approximately 47 months after resection with adjuvant therapy, 38 months for nonmetastatic, locally unresectable disease, and 17 months for metastatic disease treated with chemotherapy. Combination fluoropyrimidine-based chemotherapy regimens had better rates of disease control than other therapies. Our case series included 21 study patients, 14 of whom required resection and 7 who had metastatic disease. The rates of median survival were 40.2 + 31.9 months in those who underwent surgery and were treated with adjuvant therapy and 13.8 + 11.3 months for patients with metastatic disease.ConclusionsMultidisciplinary treatment for acinar cell carcinoma of the pancreas should be considered due to the rarity of the disease and its lack of high-level therapeutic data. Progress in the molecular analysis of this tumor may improve outcomes through the use of personalized therapy based on underlying tumor mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|